Posted by Michael Wonder on 27 Nov 2016
Janssen submits application to EMA seeking approval of anti-interleukin 23 monoclonal antibody guselkumab for the treatment of moderate to severe plaque psoriasis
25 November 2016 - Janssen-Cilag announced today the submission of a marketing authorisation application to the EMA seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis.
Guselkumab is a human monoclonal antibody that targets the protein interleukin 23, which has been shown to play a key role in the development of immune-mediated inflammatory diseases.
